Federal investment and regulatory benefits draw biotech firms to Switzerland

Article

The country is home to 20% of biotechs headquartered in Europe.

An airport arrivals screen shows a flight to Geneva boarding. Image credit: ©WD Stockphotos – stock.adobe.com

Switzerland hosts the headquarters for many new biotech companies. Image credit: ©WD Stockphotos – stock.adobe.com

Regulatory benefits and financial incentives have made Switzerland an appealing location for European biotech firms. A report by IQVIA indicates the country is becoming a hub for companies in the region.1 The 2023 Swiss Biotech Report noted that 20% of European biotech companies call the country home. The biotech sector also comprises a significant percentage of new companies in Switzerland. Out of 265 companies newly headquartered there last year, 63 were in the biotech space.

Jörg Schläpfer, director of Management Services and International Affairs at Swissmedic, said the agency’s high approval rates were partially to thank for the influx of new companies.2 “Through collaborations with international partners, we facilitate controlled and rapid global access to promising products for drug developers,” Schläpfer said.

He added that the ability to commercialise these therapies without large pharma support ensures “patients can benefit as quickly as possible from innovative therapies which are safe and of high quality.”

Switzerland’s infrastructure plays a large part in drawing non-European companies to cities like Basel, Geneva, Zurich and Lucerne. Along with regulatory benefits, federal investment incentivises global biotech firms to establish headquarters in Switzerland. Of the new companies that settled in Switzerland last year, 23 were US-based, indicating broad international appeal. Experts at IQVIA said the trend is projected to continue.

Isma Hachi, director of Emerging Biopharma, IQVIA, commented on these factors as revealed by the firm’s research.2 “Many biotechs based outside Europe choose Switzerland for setting up their European HQ, driven by a business-friendly environment and a deep talent pool,” Hachi said. “Our research shows +25% higher rate of availability in European markets for medicines, developed by Swiss-based biotech companies versus average, biotech launches in the past five years.”

References

1. Emerging Biopharma’s Contribution to Innovation. IQVIA Report. Published June 13, 2022. Accessed May 30, 2023.
2. Latest research shows 20% of European biotechs now headquartered in Switzerland. News release. RHA Communications, May 23, 2023. https://www.swissbiotech.org/listing/swiss-biotech-report-2023-shows-sector-weathers-global-disruption-well-and-continues-to-play-a-leading-role-driving-global-healthcare-innovation/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.